Mobile website
Clinical Research
Effect of trastuzumab combined with paclitaxel and S-1 chemotherapy on treating metastatic HER2-positive advanced gastric carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the clinical efficacy and safety of trastuzumab combined with paclitaxel and “tegafur gimeracil and oteracil potassium” (S-1) chemotherapy in the second-line treatment for HER-2-positive advanced gastric carcinoma．Methods： Seventeen by gone cases of chemo-refractory advanced gastric carcinoma treated in Affiliated Cancer Hospital of Xinjiang Medical University from January 2012 to March 2014 were included in this study. The patients were previously treated with chemotherapy regimen of oxalipaltin combined with fluorouracil. Therapeutic effect and adverse reactions were evaluated in the second-line treatment with trastuzumab combined with paclitaxel and S-1．Results：The therapeutic effect of all the 17 patients were evaluated with partial alleviated in 4 cases, stable disease in 7 cases and disease progression in 6 cases, the objective effective rate was 4/17 and disease control rate was 11/17；The median progress free survival time (PFS) was 6.5 months (95% CI 4.9-11.1) and median overall survival time (OS) was 11.9 months (95% CI 8.7-13.8)．Among the 17 cases，loss of appetite, neutropenia, fatigue and hair loss were the most frequent adverse events, and most of them were at level 1-2．In the aspect of possible trastuzumab-related adverse events, no obvious decreasing in left ventricular ejection fraction and adverse events related to cardiac was observed. Conclusion:Second-line chemotherapy of trastuzumab combined with paclitaxel and S-1 is effective and safe in treating patients with HER2-positive advanced gastric carcinoma.
Keywords:
Project Supported:
Project supported by the Natural Science Foundation of Xinjiang Uygur Autonomous Region（No. 2013211A067）, and the Scientific Research Innovation Foundation of Xinjiang Medical University (No. XJC201384)
Clc Number:
